🇺🇸 FDA

Intelligence · Clinical Pipeline

Kura Oncology Pipeline

All ClinicalTrials.gov programs at Kura Oncology — phase, modality, and trial IDs.

Programs
25

Quick answer

Kura Oncology has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  3. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  4. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  5. Tipifarnib

    Kura Oncology

    HNSCC

    phase 2 small molecule completed

    1 trial

  6. Tipifarnib

    Kura Oncology

    HRAS Gene Mutation

    phase 2 small molecule completed

    1 trial

  7. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  8. Tipifarnib

    Kura Oncology

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  9. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  10. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  11. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

  12. Ziftomenib, Ziftomenib

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  14. Darlifarnib

    Kura Oncology

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial

  15. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  16. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  17. Tipifarnib

    Kura Oncology

    NSCLC

    phase 1 small molecule terminated

    1 trial

  18. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  19. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  20. Ziftomenib

    Kura Oncology

    Relapsed/Refractory KMT2A-r Acute Leukemia

    phase 1 small molecule active

    1 trial

  21. Ziftomenib

    Kura Oncology

    AML

    phase 1 small molecule active

    1 trial

  22. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Ziftomenib

    Kura Oncology

    KMT2A-rearranged

    phase 1 small molecule active

    1 trial

  24. Ziftomenib

    Kura Oncology

    Refractory Acute Leukemia

    phase 1 small molecule active

    1 trial

  25. ziftomenib

    Kura Oncology

    Gastrointestinal Stromal Tumor (GIST)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Kura Oncology have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.